Special Issue "Real-World Data for Health Research: The Potential of Longitudinal Data Mining"

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Health Care Sciences & Services".

Deadline for manuscript submissions: 30 December 2021.

Special Issue Editors

Dr. Sara Malo
E-Mail Website
Guest Editor
Department of Preventive Medicine and Public Health, University of Zaragoza, Institute for Health Research Aragón (IIS Aragón), Grupo de investigación en Servicios Sanitarios de Aragon (GRISSA), Spain
Interests: health services research; pharmacoepidemiology; drug utilization studies; drug adherence; cardiovascular drug prevention
Dr. Antonio Gimeno-Miguel
E-Mail Website
Guest Editor
Aragon Health Sciences Institute (IACS), Institute for Health Research Aragón (IIS Aragón), EpiChron Research Group, REDISSEC, Miguel Servet University Hospital, Zaragoza, Spain.
Interests: epidemiology; public health; chronic diseases; multimorbidity; real-world data
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

In the era of digitalization, both the availability and the utilization of demographic, social, clinical, health, work and lifestyle information are increasing and essential for obtaining real-world evidence (RWE). The evidence coming from large-scale observational studies complements well that traditionally obtained through clinical trials.

Integration and analysis of large real-world data (RWD) sets is performed by means of data mining processes. In this way, data mining allows to find repetitive patterns that explain data behaviour. In the field of health research, for instance, it represents an opportunity to conduct clinical-epidemiological studies aimed at identifying profiles of patients with different probabilities of presenting a specific heatlh outcome, subjects who would benefit the most from a public health intervention, or those who would respond better than others to a pharmacological treatment. Longitudinal data mining can also be useful to explore how diseases tend to cluster in the form of morbidity patterns in the population and how these patterns evolve over time following specific disease trajectories.

Generating RWE on this area may help us fill the existing knowledge gaps and support different stakeholders involved in healthcare decisions to take the most effective measures for the improvement of both patients’ quality of life and healthcare systems’ performance.

On this basis, we consider of special relevance the potential of integration and mining of health-related longitudinal data in the achievement of the best RWE on health research. Papers addressing this topic are invited for this Special Issue, especially those combining a high academic standard and a practical focus on providing relevant RWE for clinical paractice and health systems.

Dr. Sara Malo
Dr. Antonio Gimeno-Miguel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • real-world data
  • data management
  • data analyses
  • big data
  • health care utilization
  • drug utilization study

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Article
Evolution of Cardiovascular Risk Factors in a Worker Cohort: A Cluster Analysis
Int. J. Environ. Res. Public Health 2021, 18(11), 5610; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18115610 - 24 May 2021
Viewed by 552
Abstract
The identification of the cardiovascular risk factor (CVRF) profile of individual patients is key to the prevention of cardiovascular disease (CVD), and the development of personalized preventive approaches. Using data from annual medical examinations in a cohort of workers, the aim of the [...] Read more.
The identification of the cardiovascular risk factor (CVRF) profile of individual patients is key to the prevention of cardiovascular disease (CVD), and the development of personalized preventive approaches. Using data from annual medical examinations in a cohort of workers, the aim of the study was to characterize the evolution of CVRFs and the CVD risk score (SCORE) over three time points between 2009 and 2017. For descriptive analyses, mean, standard deviation, and quartile values were used for quantitative variables, and percentages for categorical ones. Cluster analysis was performed using the Kml3D package in R software. This algorithm, which creates distinct groups based on similarities in the evolution of variables of interest measured at different time points, divided the cohort into 2 clusters. Cluster 1 comprised younger workers with lower mean body mass index, waist circumference, blood glucose values, and SCORE, and higher mean HDL cholesterol values. Cluster 2 had the opposite characteristics. In conclusion, it was found that, over time, subjects in cluster 1 showed a higher improvement in CVRF control and a lower increase in their SCORE, compared with cluster 2. The identification of subjects included in these profiles could facilitate the development of better personalized medical approaches to CVD preventive measures. Full article
Show Figures

Figure 1

Article
Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data
Int. J. Environ. Res. Public Health 2021, 18(9), 4754; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18094754 - 29 Apr 2021
Viewed by 1140
Abstract
We aimed to identify and compare medication profiles in populations with polypharmacy between 2005 and 2015. We conducted a cross-sectional study using information from the Computerized Database for Pharmacoepidemiologic Studies in Primary Care (BIFAP, Spain). We estimated the prevalence of therapeutic subgroups in [...] Read more.
We aimed to identify and compare medication profiles in populations with polypharmacy between 2005 and 2015. We conducted a cross-sectional study using information from the Computerized Database for Pharmacoepidemiologic Studies in Primary Care (BIFAP, Spain). We estimated the prevalence of therapeutic subgroups in all individuals 15 years of age and older with polypharmacy (≥5 drugs during ≥6 months) using the Anatomical Therapeutic Chemical classification system level 4, by sex and age group, for both calendar years. The most prescribed drugs were proton-pump inhibitors (PPIs), statins, antiplatelet agents, benzodiazepine derivatives, and angiotensin-converting enzyme inhibitors. The greatest increases between 2005 and 2015 were observed in PPIs, statins, other antidepressants, and β-blockers, while the prevalence of antiepileptics was almost tripled. We observed increases in psychotropic drugs in women and cardiovascular medications in men. By patient´s age groups, there were notable increases in antipsychotics, antidepressants, and antiepileptics (15–44 years); antidepressants, PPIs, and selective β-blockers (45–64 years); selective β-blockers, biguanides, PPIs, and statins (65–79 years); and in statins, selective β-blockers, and PPIs (80 years and older). Our results revealed important increases in the use of specific therapeutic subgroups, like PPIs, statins, and psychotropic drugs, highlighting opportunities to design and implement strategies to analyze such prescriptions’ appropriateness. Full article
Article
Changes in Multimorbidity and Polypharmacy Patterns in Young and Adult Population over a 4-Year Period: A 2011–2015 Comparison Using Real-World Data
Int. J. Environ. Res. Public Health 2021, 18(9), 4422; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18094422 - 21 Apr 2021
Viewed by 637
Abstract
The pressing problem of multimorbidity and polypharmacy is aggravated by the lack of specific care models for this population. We aimed to investigate the evolution of multimorbidity and polypharmacy patterns in a given population over a 4-year period (2011–2015). A cross-sectional, observational study [...] Read more.
The pressing problem of multimorbidity and polypharmacy is aggravated by the lack of specific care models for this population. We aimed to investigate the evolution of multimorbidity and polypharmacy patterns in a given population over a 4-year period (2011–2015). A cross-sectional, observational study among the EpiChron Cohort, including anonymized demographic, clinical and drug dispensation information of all users of the public health system ≥65 years in Aragon (Spain), was performed. An exploratory factor analysis, stratified by age and sex, using an open cohort was carried out based on the tetra-choric correlations among chronic diseases and dispensed drugs during 2011 and compared with 2015. Seven baseline patterns were identified during 2011 named as: mental health, respiratory, allergic, mechanical pain, cardiometabolic, osteometabolic, and allergic/derma. Of the epidemiological patterns identified in 2015, six were already present in 2011 but a new allergic/derma one appeared. Patterns identified in 2011 were more complex in terms of both disease and drugs. Results confirmed the existing association between age and clinical complexity. The systematic associations between diseases and drugs remain similar regarding their clinical nature over time, helping in early identification of potential interactions in multimorbid patients with a high risk of negative health outcomes due to polypharmacy. Full article

Review

Jump to: Research

Review
Real-World Utilization of Target- and Immunotherapies for Lung Cancer: A Scoping Review of Studies Based on Routinely Collected Electronic Healthcare Data
Int. J. Environ. Res. Public Health 2021, 18(14), 7679; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18147679 - 19 Jul 2021
Viewed by 373
Abstract
Routinely collected electronic healthcare data (rcEHD) have a tremendous potential for enriching pre-marketing evidence on target- and immunotherapies used to treat lung cancer (LC). A scoping review was performed to provide a structured overview of available rcEHD-based studies on this topic and to [...] Read more.
Routinely collected electronic healthcare data (rcEHD) have a tremendous potential for enriching pre-marketing evidence on target- and immunotherapies used to treat lung cancer (LC). A scoping review was performed to provide a structured overview of available rcEHD-based studies on this topic and to support the execution of future research by facilitating access to pertinent literature both for study design and benchmarking. Eligible studies published between 2016 and 2020 in PubMed and ISI Web of Science were searched. Data source and study characteristics, as well as evidence on drug utilization and survival were extracted. Thirty-two studies were included. Twenty-six studies used North American data, while three used European data only. Thirteen studies linked ≥1 data source types among administrative/claims data, cancer registries and medical/health records. Twenty-nine studies retrieved cancer-related information from medical records/cancer registries and 31 studies retrieved information on drug utilization or survival from medical records or administrative/claim data. Most part of studies concerned non-small-cell-LC patients (29 out of 32) while none focused on small-cell-LC. Study cohorts ranged between 85 to 81,983 patients. Only two studies described first-line utilization of immunotherapies. Results from this review will serve as a starting point for the execution of future rcEHD-based studies on innovative LC pharmacotherapies. Full article
Show Figures

Figure 1

Back to TopTop